Back
5-Alpha-Reductase Inhibitors and Combination Therapy.
Journal article

5-Alpha-Reductase Inhibitors and Combination Therapy.

  • Füllhase C Department of Urology, University of Rostock, Ernst-Heydemann-Str. 6, Rostock 18057, Germany. Electronic address: Claudius.fuellhase@uni-rostock.de.
  • Schneider MP Department of Health Science and Technology, Swiss Federal Institute of Technology Zurich, Brain Research Institute, University of Zurich, Winterthurerstrasse 190, Zürich 8057, Switzerland.
  • 2016-08-01
Published in:
  • The Urologic clinics of North America. - 2016
5-Alpha-reductase inhibitors
Combination drug therapy
Dutasteride
Finasteride
Lower urinary tract symptoms
Prostatic hyperplasia
5-alpha Reductase Inhibitors
Adrenergic alpha-Antagonists
Drug Therapy, Combination
Humans
Male
Prostatic Hyperplasia
Testosterone
English By inhibiting the conversion from testosterone to dihydrotestosterone 5-Alpha reductase inhibitors (5ARIs) are able to hinder prostatic growth, shrink prostate volumes, and improve BPH-related LUTS. 5ARIs are particularly beneficial for patients with larger prostates (>30-40ml). Generally the side effects of 5ARI treatment are mild, and according to the FORTA classification 5ARIs are suitable for frail elderly. 5ARI / alpha-blocker (AB) combination therapy showed the best symptomatic outcome and risk reduction for clinical progression. Combining Phosphodieseterase type 5 inhbibitors (PDE5Is) with 5ARIs counteracts the negative androgenic sexual side effects of 5ARIs, and simultaneously combines their synergistic effects on LUTS.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/277258
Statistics
Document views: 29 File downloads: